KLOW

What it is

KLOW is not a single peptide. It is a pre-mixed blend of four: GHK-Cu (the copper peptide, known for skin and hair), BPC-157 (associated with tissue and gut healing in animal studies), TB-500 (a thymosin beta-4 fragment associated with repair and recovery) and KPV (a three-amino-acid anti-inflammatory fragment of alpha-MSH). Think of it as the GLOW blend with KPV added. The name is a marketing label used by research-peptide sellers, not a recognised compound.

The vial we stock is 80 mg: 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 and 10 mg KPV. The appeal is convenience: one vial and one injection instead of four. The catch is that nobody has studied this combination in people, and the evidence for several of the individual ingredients is thin too.

History

The blend has no research history of its own. It appeared in the research-peptide market in the mid-2020s as an extension of GLOW, with KPV added for its anti-inflammatory angle. The ingredients are older: GHK-Cu was identified in the early 1970s, BPC-157 in the early 1990s, KPV was identified as the active anti-inflammatory fragment of alpha-MSH in the 1990s, and TB-500 is derived from thymosin beta-4, which has been studied since the 1980s.

How it works

There is no mechanism data for the combination, only for the parts. GHK-Cu delivers copper and influences collagen production and gene expression linked to wound healing. BPC-157 is thought to promote new blood vessel growth and repair signalling. TB-500 is thought to affect actin, a protein involved in cell movement. KPV is thought to dampen inflammation by suppressing NF-kB signalling in immune and gut cells. Whether the four add up, overlap or do nothing together has not been tested.

Dosage

• There is no standard dose. Because the ratio is fixed (5:1:1:1), people usually dose by the BPC-157, TB-500 and KPV content, since those are the lower-dose components.
• A commonly reported range is about 0.25-0.5 mg each of BPC-157, TB-500 and KPV per injection, which brings roughly 1.25-2.5 mg of GHK-Cu with it, once daily or a few times a week.
• Typical courses reported are 4-8 weeks, then a break. These figures are extrapolated from the individual peptides and community reports, not from trials.
• You cannot adjust one component without changing the others. If you want a different dose of any one of them, separate vials are the only way.

How it is taken

• Subcutaneous injection into belly fat with a 29-31G insulin syringe is the usual route.
• Some users inject near the area they care about, such as the face or scalp for skin and hair goals, or close to an injury. The evidence that this works better than injecting elsewhere is weak.
• Rotate injection sites to reduce irritation and lumps.

How to reconstitute

• For the 80 mg vial (50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, 10 mg KPV), add 2 ml of bacteriostatic water. That gives 40 mg/ml of total blend.
• On a 1 ml / 100-unit insulin syringe, 5 units (0.05 ml) is 2 mg of blend: 1.25 mg GHK-Cu, 0.25 mg BPC-157, 0.25 mg TB-500 and 0.25 mg KPV.
• 10 units (0.1 ml) is 4 mg of blend: 2.5 mg GHK-Cu and 0.5 mg each of BPC-157, TB-500 and KPV.
• Always work from the amounts on your own vial's label, because sellers sometimes use different ratios.
• Add the water slowly down the inside wall of the vial. Swirl gently to dissolve. Do not shake.

How it should arrive

Sealed glass vial with an intact crimped cap and a powder cake at the bottom. Because GHK-Cu is blue-green, the powder should look pale blue to teal, not pure white. A fully white powder in a vial labelled with 50 mg GHK-Cu suggests the GHK-Cu is missing or heavily under-dosed.

How it should look once reconstituted

A clear blue or blue-green solution with no cloudiness, flecks or residue. A colourless solution is a red flag. A very pale tint can be normal at low GHK-Cu amounts, but 50 mg in a vial should give an obvious colour.

What to expect, and when

• Wound or injury recovery: anecdotally 2-6 weeks, based on the BPC-157 and TB-500 components.
• Skin texture and tone: 4-8 weeks at the earliest, based on GHK-Cu evidence.
• Hair changes: GHK-Cu hair studies run 3-6 months, so do not expect anything faster.
• Gut or inflammatory symptoms: 1-3 weeks is what is reported for KPV and BPC-157 on their own.
• If you notice nothing after 6-8 weeks of consistent use, the realistic conclusion is that it is not doing anything for you.

Side effects

• Most reports describe the individual components as well tolerated, but that is mostly self-reported.
• Injection-site redness, itching, stinging or small lumps. GHK-Cu can cause temporary blue-ish discolouration at the site.
• Occasional headache, tiredness or flushing, reported for the BPC-157 and TB-500 components.
• With four ingredients in one injection you cannot tell which one caused a reaction without stopping and testing them separately.

Risks

• No human safety data exists for the combination. The safety picture is borrowed from the individual peptides, and BPC-157, TB-500 and KPV have little or no controlled human data between them.
• BPC-157 and TB-500 are both thought to promote blood vessel growth and tissue repair. That is why they are interesting, and also why long-term safety, including tumour risk, has not been ruled out. If you have a cancer history or a suspected tumour, this is a good reason to avoid them.
• KPV works by suppressing inflammation, and suppressing inflammation systemically is not always what you want, for example around an infection.
• Quality varies a lot. A four-way blend is harder to verify than a single peptide: a seller can under-dose or leave out a component and the vial can still look plausible. Independent third-party testing of the blend is the only real check.
• You may be paying for 50 mg of GHK-Cu you do not need. It is cheap on its own and has decent topical evidence.
• BPC-157 and TB-500 are both banned for competitive athletes under WADA rules. None of these are licensed medicines for human use.

Potential gains

• Convenience: one vial and one injection in place of four.
• Skin firmness and tone, and possibly hair density, from the GHK-Cu component. This is the best-evidenced part, mostly from topical use.
• Soft-tissue and wound recovery, based on animal studies and anecdote for BPC-157 and TB-500.
• Possible anti-inflammatory and gut support from KPV, based on animal and small-scale studies.
• No trial shows the combination works better than the individual peptides.

Other useful information

KLOW is the same idea as GLOW with KPV added, so everything on the GLOW page applies here too. If skin or hair is the goal, topical GHK-Cu has the strongest evidence and lowest risk. If gut inflammation is the goal, KPV and BPC-157 are available separately, which lets you control each dose. KLOW only makes sense if you specifically want all four and accept the fixed ratio. Read the label rather than going by the name, as sellers' versions differ.